TY - JOUR
T1 - From prospective biobanking to precision medicine
T2 - BIO-RAIDs - an EU study protocol in cervical cancer
AU - RAIDs consortium
AU - Ngo, Charlotte
AU - Samuels, Sanne
AU - Bagrintseva, Ksenia
AU - Slocker, Andrea
AU - Hupé, Philippe
AU - Kenter, Gemma
AU - Popovic, Marina
AU - Samet, Nina
AU - Tresca, Patricia
AU - von der Leyen, Heiko
AU - Deutsch, Eric
AU - Rouzier, Roman
AU - Belin, Lisa
AU - Kamal, Maud
AU - Scholl, Suzy
N1 - Publisher Copyright:
© 2015 Ngo et al.
PY - 2015/11/4
Y1 - 2015/11/4
N2 - Background: Cervical cancer (CC) is -second to breast cancer- a dominant cause of gynecological cancer-related deaths worldwide. CC tumor biopsies and blood samples are of easy access and vital for the development of future precision medicine strategies. Design: BIO-RAIDs is a prospective multicenter European study, presently recruiting patients in 6 EU countries. Tumor and liquid biopsies from patients with previously non-treated cervical cancer (stages IB2-IV) are collected at defined time points. Patients receive standard primary treatment according to the stage of their disease. 700 patients are planned to be enrolled. The main objectives are the discovery of -dominant molecular alterations, -signalling pathway activation, and -tumor micro-environment patterns that may predict response or resistance to treatment. An exhaustive molecular analysis is performed using 1° Next generation sequencing, 2° Reverse phase protein arrays and 3° Immuno-histochemistry. Discussion: The clinical study BIO-RAIDs is activated in all planned countries, 170 patients have been recruited till now. This study will make an important contribution towards precision medicine treatments in cervical cancer. The results will support the development of clinical practice guidelines for cervical cancer patients to improve their prognosis and their quality of life. Trial registration: Clinicaltrials.gov: NCT02428842 , registered 10 February 2015.
AB - Background: Cervical cancer (CC) is -second to breast cancer- a dominant cause of gynecological cancer-related deaths worldwide. CC tumor biopsies and blood samples are of easy access and vital for the development of future precision medicine strategies. Design: BIO-RAIDs is a prospective multicenter European study, presently recruiting patients in 6 EU countries. Tumor and liquid biopsies from patients with previously non-treated cervical cancer (stages IB2-IV) are collected at defined time points. Patients receive standard primary treatment according to the stage of their disease. 700 patients are planned to be enrolled. The main objectives are the discovery of -dominant molecular alterations, -signalling pathway activation, and -tumor micro-environment patterns that may predict response or resistance to treatment. An exhaustive molecular analysis is performed using 1° Next generation sequencing, 2° Reverse phase protein arrays and 3° Immuno-histochemistry. Discussion: The clinical study BIO-RAIDs is activated in all planned countries, 170 patients have been recruited till now. This study will make an important contribution towards precision medicine treatments in cervical cancer. The results will support the development of clinical practice guidelines for cervical cancer patients to improve their prognosis and their quality of life. Trial registration: Clinicaltrials.gov: NCT02428842 , registered 10 February 2015.
KW - Biobanking
KW - Cervical cancer
KW - Clinical trial operations
KW - HPV typing
KW - International trial
KW - Molecular profiling
KW - Next generation sequencing
KW - Patient stratification
KW - Precision medicine
KW - Prospective European biobanking study
KW - Quality control of pelvic radiotherapy
KW - Reverse phase protein array
KW - Targeted therapy
KW - Tumor micro environment
UR - http://www.scopus.com/inward/record.url?scp=84946214063&partnerID=8YFLogxK
U2 - 10.1186/s12885-015-1801-0
DO - 10.1186/s12885-015-1801-0
M3 - Article
C2 - 26531748
AN - SCOPUS:84946214063
SN - 1471-2407
VL - 15
JO - BMC Cancer
JF - BMC Cancer
IS - 1
M1 - 842
ER -